Luspatercept-aamt Shows Efficacy Treating Anemia Due to Myelodysplastic Syndromes
June 19th 2023Trial results demonstrated that 58.5% of individuals receiving luspatercept-aamt (Reblozyl; Bristol Myers Squibb) achieved the primary endpoint of red blood cell transfusion independence of at least 12 weeks.
Read More
Axi-Cel Use in Patients With Large B-Cell Lymphoma Leads to Longer Overall Survival
June 16th 2023A single dose of axicabtagene ciloleucel in patients with large B-cell lymphoma led to significantly higher overall survival and progression-free survival rates, as well as improvements in quality of life and faster recovery in comparison to standard care therapy.
Read More
Have Children Truly Ever Been ‘Therapeutic Orphans?’
June 16th 2023Imposing the FDA on-label/off-label framework on administratively defined "children" resulted in a regulatory demand for pediatric studies that had no basis in clinical medicine, with the exception of the small group of preterm newborns.
Read More
AmerisourceBergen Corporate Partnerships Team Aims to Support, Guide Pharmacy Customers
June 16th 2023Claire Biermaas, president of Corporate Partnerships at AmerisourceBergen, discussed the Corporate Partnerships Team, which works closely with pharmacy customers to guide their processes and help execute their vision.
Watch